Unbiased AI-powered news
Copper Sky Capital is raising a second fund of $300 million. The firm previously invested in Etched, a chip designer now preparing to ship its first product.
focustaiwan.twCopper Sky Capital, a Phoenix-based venture firm, is raising a $300 million second fund, according to a regulatory filing. The firm made an early investment in Etched, a four-year-old chip designer now valued at $5 billion. Etched announced this week that its first chip was manufactured by TSMC earlier this year and that systems using the chip are scheduled to ship to customers later this summer.
Sky participated in Etched's $120 million Series A round two years ago. The firm secured its allocation in part by offering to help the startup move chip production to Arizona. Jack Selby, who founded Copper Sky in 2021 after serving as a managing director at Thiel Capital, holds a board seat at the Arizona Commerce Authority.
He told TechCrunch that Etched understood the firm's connections to the state's semiconductor industry when the investment was made.
Sky's first fund of $115 million focused on Arizona and Southwest companies. The firm has since broadened its scope to hardware and defense startups that can establish manufacturing operations in Arizona. Etched and other chip designers face competition for production capacity at TSMC's Taiwan facilities.
Copper Sky has expressed hope that Etched will eventually use TSMC's Arizona factory to ease those constraints.
Single source — no framing comparison available.
ndtv.comTesla recorded lower sales in the United States during the first half of 2026. European deliveries rose sharply after price cuts and higher fuel prices linked to the Iran war.
The Court of Justice of the European Union confirmed a 4.1 billion euro penalty against Google for bundling its search and browser apps as defaults on Android devices. The ruling ends Google's appeals process that began after the original 2018 decision.
pbs.orgThe Centers for Medicare and Medicaid Services last month proposed rules to group reformulated drugs with their originals for negotiation eligibility. The changes target biologics switched from intravenous to subcutaneous forms and would take effect with the 2029 price applicabil…